CISATRACURIUM BESYLATE INJECTION SOLUTION

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Bahan aktif:

CISATRACURIUM (CISATRACURIUM BESYLATE)

Boleh didapati daripada:

ACCORD HEALTHCARE INC

Kod ATC:

M03AC11

INN (Nama Antarabangsa):

CISATRACURIUM

Dos:

2MG

Borang farmaseutikal:

SOLUTION

Komposisi:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

Laluan pentadbiran:

INTRAVENOUS

Unit dalam pakej:

10 ML

Jenis preskripsi:

Prescription

Kawasan terapeutik:

NEUROMUSCULAR BLOCKING AGENTS

Ringkasan produk:

Active ingredient group (AIG) number: 0133260001; AHFS:

Status kebenaran:

APPROVED

Tarikh kebenaran:

2016-09-01

Ciri produk

_Cisatracurium Besylate Injection_
_ Product Monograph Page 1 of 32 _
PRODUCT MONOGRAPH
PR
CISATRACURIUM BESYLATE INJECTION
Solution for injection; 20 mg / 10 mL (2 mg / mL) cisatracurium (as
cisatracurium besylate)
(Multiple dose vial)
House Standard
NON-DEPOLARIZING SKELETAL NEUROMUSCULAR BLOCKING AGENT
Sterile solution
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR WITH ITS
ACTIONS, CHARACTERISTICS, AND HAZARDS.
Accord Healthcare Inc.
3535 boul. St. Charles, Suite 704
Kirkland, QC H9H 5B9
Canada
Submission Control No: 180494
Date of Preparation:
August 31, 2016
_Cisatracurium Besylate Injection_
_ Product Monograph Page 2 of 32 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................3
SUMMARY PRODUCT INFORMATION
.....................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS
................................................................................................3
WARNINGS AND
PRECAUTIONS...............................................................................4
ADVERSE
REACTIONS.................................................................................................9
DRUG INTERACTIONS
................................................................................................10
DOSAGE AND ADMINISTRATION
............................................................................11
OVERDOSAGE
..............................................................................................................17
ACTION AND CLINICAL PHARMACOLOGY
..........................................................17
STORAGE AND
STABILITY........................................................................................24
SPECIAL HANDLING INSTRUCTIONS
.....................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................